192330-11-3

Basic information

• Product Name: 4-Boc-piperazine-2-carboxylic acid
• Synonyms: 4-BOC-PIPERAZINE-2-(R)-CARBOXYLIC ACID;(4-N-BOC)PIPERAZINE(2R) COOH;(R)-PIPERAZINE-1,3-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER;(R)-4-(TERT-BUTOXYCARBONYL)PIPERAZINE-2-CARBOXYLIC ACID;(R)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID;(R)-4-BOC-PIPERAZINE-2-CARBOXYLIC ACID;(S)-4-Boc-2-piperazine carboxylic acid;(R)-1-Boc-piperazine-3-carboxylic acid
• CAS NO: 192330-11-3
• Molecular Formula: C₁₀H₁₈N₂O₄
• Molecular Weight: 230.26
• Product Categories: pharmacetical;Piperaizine
• Mol File: 192330-11-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 231-239 ºC
• Boiling Point: 371.785 °C at 760 mmHg
• Flash Point: 178.649 °C
• Appearance: /
• Density: 1.193 g/cm³
• Vapor Pressure: 1.5E-06mmHg at 25°C
• Refractive Index: 1.495
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.20±0.20(Predicted)
• CAS DataBase Reference: 4-Boc-piperazine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Boc-piperazine-2-carboxylic acid(192330-11-3)
• EPA Substance Registry System: 4-Boc-piperazine-2-carboxylic acid(192330-11-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-43-36
• Safety Statements: 26-36/37/39-36/37
• Hazardous Substances Data: 192330-11-3(Hazardous Substances Data)

Usage

Uses

4-(tert-Butoxycarbonyl)piperazine-2-carboxylic Acid is used in preparation of substituted Azacyles as TRMP8 modulators.

InChI:InChI=1/C10H18N2O4/c1-10(2,3)16-9(15)12-5-4-11-7(6-12)8(13)14/h7,11H,4-6H2,1-3H3,(H,13,14)/t7-/m1/s1

Upstream product

• 74651-77-7 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile 

Downstream Products

• 173774-48-6 (R)-piperazine-1,2,4-tricarboxylic acid 1,4-di-tert-butyl ester 
• 637027-27-1 1-[4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl-4-boc-piperazine-2-(R)-carboxylic acid 
• 192330-12-4 2(R)-4-(t-butoxycarbonyl)-1-(4-(4-chlorophenoxy)-benzenesulfonyl)-piperazine-2-carboxylic acid 

Relevant articles and documents

Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof

The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

The invention relates to compounds of the formula I STR1 in which Q is a divalent radical having four ring atoms which together with C* and N form a six-membered ring, each of these four ring atoms being unsubstituted or substituted by a suitable substituent and at least one being a heteroatom selected from O, N and S, with the remainder being carbon atoms; and Ar is an aryl or heteroaryl group. The invention further relates to pharmaceutically acceptable prodrugs and pharmaceutically acceptable salts of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases, especially MMPs or TNF-α, by administering a compound of the formula I or a salt or prodrug thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, salts, and prodrugs.